Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H25N3O |
Molecular Weight | 347.4542 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)C(=NC2CCN(CCc3c[nH]c4ccccc34)CC2)O
InChI
InChIKey=JXZZEXZZKAWDSP-UHFFFAOYSA-N
InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
Molecular Formula | C22H25N3O |
Molecular Weight | 347.4542 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB08950
Sources: https://www.drugbank.ca/drugs/DB08950
Indoramin is an alpha-1 selective antagonist of adrenergic receptor, sold under trade names Baratol and Doralese, and now available as a generic. It has no reflex tachycardia and direct myocardial depression action and is used to treat benign prostate hyperplasia (as 20 mg tablets) or reduce blood pressure (as 25 mg strength tablets). It was also investigated as a treatment of a migraine and congestive heart failure.
CNS Activity
Originator
Sources: https://www.google.com/patents/US3527761
Curator's Comment:: # Wyeth John & Brother Ltd
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028 |
8.4 null [pKi] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028 |
7.4 null [pKi] | ||
Target ID: CHEMBL223 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9135028 |
6.8 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DORALESE Approved UseIndoramin 20 mg Tablets are used for a condition called ‘benign prostatic hyperplasia’ or BPH. The prostate is a gland found underneath the bladder in men. It surrounds the tube (called the urethra) which carries urine from the bladder to the outside of the body. |
|||
Primary | BARATOL Approved UseBaratol Tablets are used to reduce high blood pressure. |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/49624 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A double-blind comparison of indoramin and propranolol in the treatment of moderate to severe essential hypertension. | 1983 |
|
Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin. | 1986 Feb |
|
Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. | 1999 Apr 16 |
|
A double-blind randomized placebo-controlled trial of oral indoramin to treat chronic anal fissure. | 2001 May |
|
[Migraine: a disease, not a symptom]. | 2002 Jan 1 |
|
Drug-related hyperprolactinemia. | 2003 Feb |
|
Functional characterisation of alpha(1)-adrenoceptors in denervated rat vas deferens. | 2003 Jul |
|
[Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database]. | 2003 Mar-Apr |
|
Recent advances in the pharmacotherapy of chronic anal fissure: an update. | 2008 Jul |
|
Optimizing prophylactic treatment of migraine: Subtypes and patient matching. | 2008 Oct |
Patents
Sample Use Guides
The recommended dose is one tablet (20 mg) twice a day. The tablet should be swallowed with water. Some elderly patients may need just one tablet at night. The patient’s doctor may increase their dose to a maximum total daily dose of 100 mg. The patient must not take more than their doctor has recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6133954
Binding of indoramin to alpha1 receptors was studied using rat cerebral cortex membranes with [3H]prazosin to label alpha1 adrenoreceptors. Indoramin displaces prozasin with IC50 pKi of 7.61.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:59:14 UTC 2021
by
admin
on
Sat Jun 26 09:59:14 UTC 2021
|
Record UNII |
0Z802HMY7H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
||
|
WHO-VATC |
QC02CA02
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
||
|
WHO-ATC |
C02CA02
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M6280
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | Merck Index | ||
|
248-041-5
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
CHEMBL279516
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
INDORAMIN
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
33625
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
0Z802HMY7H
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
5784
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | RxNorm | ||
|
26844-12-2
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
D007217
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
3064
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
C65916
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
SUB08184MIG
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
1443
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
26844-12-2
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY | |||
|
DB08950
Created by
admin on Sat Jun 26 09:59:14 UTC 2021 , Edited by admin on Sat Jun 26 09:59:14 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |